of 31 /31

Dvt Prophylaxis 2

Embed Size (px)

Citation preview

Page 1: Dvt Prophylaxis 2


Page 2: Dvt Prophylaxis 2

Predisposing Factors The most common risk factors are recent surgery or hospitalization

Advanced age




Oetrogen-containing forms of hormonal contraception

Tobacco usage

Air travel ("economy class syndrome", a combination of immobility and relative dehydration)


Page 3: Dvt Prophylaxis 2

VTE Common Complication of Hospital Stay

~70% of all VTE is hospital-acquired

One of the most common complications

Commonest preventable cause of hospital


Doubles length of stay and cost

Page 4: Dvt Prophylaxis 2

VTE COMPLICATIONS: Important cause of Mortality and Morbidity

Immediate/Early: Pulmonary Embolism

Late: Post- thrombotic Syndrome

Page 5: Dvt Prophylaxis 2

Rationale for ThromboprophylaxisHigh prevalence of VTE in most

hospitalized patient groups

Adverse consequences of unprevented VTE

Effectiveness and cost-effectiveness of thromboprophylaxis

Page 6: Dvt Prophylaxis 2



Graduated compression stockings (also known as thromboembolic deterrent stockings)

Intermittent pneumatic compression (IPC) devices

Vena Cava Filter

Page 7: Dvt Prophylaxis 2

EVIDENCEThromboprophylaxis is the

number 1 ranked patient safety strategy in hospitalized patients

More than 25 published evidence-based guidelines since 1986 show clear evidence of benefit and safety.

Page 8: Dvt Prophylaxis 2


Page 9: Dvt Prophylaxis 2

American College of Chest Physicians

"In acutely ill medical patients who have been admitted to the hospital with congestive heart failure or severe respiratory disease, or who are confined to bed and have one or more additional risk factors, including active cancer, previous VTE, sepsis, acute neurologic disease, or inflammatory bowel disease, we recommend prophylaxis with low-dose unfractionated heparin-LDUH or LMWH."

LMWH may be more effective than unfractionated heparin (UFH).

If UFH is used, 5000 U 3 times daily may be more effective.

Page 10: Dvt Prophylaxis 2

KEY RECOMMENDATIONSModerate-risk general surgery

patients: low-dose unfractionated heparin (LDUH) (5,000 U bid) or low-molecular-weight heparin (LMWH) [≤ 3,400 U once daily]

Higher risk general surgery patients, we recommend thromboprophylaxis with LDUH (5,000 U tid) or LMWH (> 3,400 U daily)

Page 11: Dvt Prophylaxis 2

High-risk: combination of pharmacologic methods (LDUH three times daily or LMWH, > 3,400 U daily) with the use of graduated compression stockings and/or intermittent pneumatic compression devices

Page 12: Dvt Prophylaxis 2

Major gynecologic surgery or major, open urologic procedures- prophylaxis with LDUH two times or three times daily 

For patients undergoing elective total hip or knee arthroplasty: LMWH, Fondaparinux, or adjusted-dose vitamin K antagonist (VKA) [ (INR) target, 2.5; range, 2.0 to 3.0] (for 10 days)

Page 13: Dvt Prophylaxis 2

Hip fracture surgery (HFS): routine use of fondaparinux, LMWH, VKA (target INR, 2.5; range, 2.0 to 3.0) or LDUH. (For 10 days)

Page 14: Dvt Prophylaxis 2

All patients should receive VTE prophylaxis within 24 hours of hospital admission or surgery end time (or have documentation why no prophylaxis was given).

Page 15: Dvt Prophylaxis 2

Stockings ?In stroke patients: thigh-length stockings

are more effective than knee stockings according to the nonblinded CLOTS 2 randomized controlled trial while thigh-length stockings were not better than no stockings in the CLOTS 1 nonblinded randomized controlled trial.

It is not clear why these two trials conflict.

Page 16: Dvt Prophylaxis 2


Page 17: Dvt Prophylaxis 2

Since enoxaparin is entirely excreted by the kidneys, the manufacturers warn against its use in patients with renal insufficiency

Retrospective cohort study, Thorevska et al 2004: overall, the frequency of bleeding increased with worsening renal insufficiency, irrespective of the agent used. However minor bleeding greater with Enoxaparin in patients with severe insufficiency.

Page 18: Dvt Prophylaxis 2

Dosing in Renal PatientsDecreased dose is recommended in

renal failure or ESRD patients

For DVT prophylaxis in a patient with GFR < 30, a dose of 30 mg daily is recommended

For DVT prophylaxis in a patient with GFR > 30, full dose (40 mg daily) can be given

Page 19: Dvt Prophylaxis 2


Page 20: Dvt Prophylaxis 2


The analysis confirmed the increased thromboembolic risk in very elderly patients, but demonstrated no increased bleeding risk.

Certoparin and UFH were equally effective and safe with a reduced risk of minor bleeding complications with certoparin in the very elderly.

Page 21: Dvt Prophylaxis 2

Journal Geriatric Cardiology 2011

High prevalence of predisposing co-morbidities and acute illnesses in elderly- prophylaxis often delayed for those reasons.

A simple way to overcome this problem is to implement universal VTE prophylaxis for all hospitalized elderly patients instead of selective prophylaxis for some patients only according to individual’s risk of VTE.

Although pharmacological VTE prophylaxis is effective for most patients, a high prevalence of renal impairment

and drug interactions in the hospitalized elderly patients suggests that a multimodality approach may be more appropriate.

MUST (Multimodality Universal STat) strategy: Mechanical VTE prophylaxis, including calf and thigh compression devices

Page 22: Dvt Prophylaxis 2


Page 23: Dvt Prophylaxis 2

HITAcquired, transient, adverse drug

reaction characterized by thrombocytopenia (relative 30-50% drop from baseline) and hypercoagulability.

Caused by heparin-dependent, platelet-activating antibodies that recognize a "self" protein, platelet factor 4 (PF4), bound to heparin. The resulting platelet activation is associated with increased thrombin generation.

Page 24: Dvt Prophylaxis 2

HITCan occur early or late

There have been cases which presented with normal platelet counts

Any patient with recent exposure to any type of Heparin (UFH or LMWH) and with either, significant reductions in platelet counts, or thrombosis should be considered for HIT.

Page 25: Dvt Prophylaxis 2


Elderly patients undergoing post-surgical prophylaxis or treatment for deep venous thrombosis, orthopaedic and cardiovascular surgery.

More common with UFH than LMWH- controvercial

Page 26: Dvt Prophylaxis 2

Two Clinical Forms

Page 27: Dvt Prophylaxis 2

4T scoring system

Page 28: Dvt Prophylaxis 2


Page 29: Dvt Prophylaxis 2

MANAGEMENT PRINCIPLES Discontinue and avoid all heparin.

Give a non-heparin alternative anticoagulant.

Postpone Warfarin pending substantial platelet count recovery (give vitamin K if Warfarin has already been started)

Test for HIT antibodies.

Investigate for lower-limb deep-vein thrombosis.

Avoid prophylactic platelet transfusions.

Page 30: Dvt Prophylaxis 2


Without any form of alternate anticoagulation, >50% of patients can develop thrombosis over the next few days to weeks

Direct thrombin inhibitors such as Argatroban and Lepirudin (renally cleared and antibody formation has been shown to occur).

Page 31: Dvt Prophylaxis 2